{"url_path":"/sec/mens/10-k/2026/item-14","section_key":"item-14","section_title":"Item 14 MATERIAL MODIFICATIONS TO THE RIGHTS","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1954488/0001213900-26-057073-index.html","accession_number":"0001213900-26-057073","cik":"0001954488","ticker":"MENS","issuer_name":"Jyong Biotech Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1954488/0001213900-26-057073-index.html","primary_entity_key":"0001954488","primary_entity_name":"Jyong Biotech Ltd."},"word_count":356,"has_tables":true,"body_markdown":"** **\n\n**Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS\nOF SECURITY HOLDERS AND USE OF PROCEEDS**\n\n** **\n\nSee “Item 10. Additional\nInformation” for a description of the rights of securities holders, which remain unchanged.\n\n \n\n**Use of Proceeds**\n\n** **\n\n**Registration Statement on Form F-1, as amended (File Number 333-277725)**\n\n \n\nThe following “Use of Proceeds” information\nrelates to the registration statement on Form F-1, as amended (File Number 333-277725) for our IPO, which was declared effective by the\nSEC on June 16, 2025. In June 2025, we completed our IPO and issued and sold an aggregate of 2,666,667 ordinary shares, at a price of\n$7.50 per share for gross proceeds of US$ 20,000 thousand, before deducting underwriting discounts and other related expenses. The Company\nreceived net proceeds of approximately US$17,771 thousand. Joseph Stone Capital, LLC was the representative of the underwriters of our\nIPO.\n\n \n\nWe incurred approximately US$2,229 thousand in\nexpenses in connection with our IPO, which included approximately US$1,400 thousand in underwriting discounts, approximately US$480 thousand\nin expenses paid to or for underwriters, and approximately US$349 thousand in other expenses. None of the transaction expenses included\npayments to directors or officers of our Company or their associates, persons owning more than 10% or more of our equity securities, or\nour affiliates. None of the net proceeds we received from the IPO were paid, directly or indirectly, to any of our directors or officers\nor their associates, persons owning 10% or more of our equity securities, or our affiliates.\n\n \n\nWe received net proceeds of approximately US$17,771 thousand after\nthe deduction of approximately US$2,229 thousand of offering costs. As of the date of this annual report, we have used US$15,000 thousand\nfor a loan to Linkage Gladden Enterprise Ltd., US$2,495 thousand towards researching and developing new drugs and clinical trials, with\nthe remaining funds used for general corporate purposes. As of the date of this annual report, Linkage Gladden Enterprise Ltd has repaid\nUS$13,817,950 of the loan amount and the outstanding amount of the loan is US$1,182,050. We intend to use the remaining proceeds from\nour IPO in the manner disclosed in our registration statement on Form F-1, as amended (File Number 333-277725)."}